Colchicine: A potential therapeutic tool against COVID-19. Experience of 5 patients.
Reumatol Clin (Engl Ed)
; 17(7): 371-375, 2021.
Article
in English
| MEDLINE | ID: covidwho-1322338
ABSTRACT
COVID-19 is a newly emerged disease that has become a global public health challenge. Due to a lack of knowledge about the virus, a significant number of potential targets for using a particular drug have been proposed. Five cases with a clinical history of biopolymers in the gluteal region that developed iatrogenic allogenosis (IA) are presented here. The 5 cases were put under colchicine treatment for IA crisis and had non-specific symptoms (headache, cough without dyspnea, and arthralgias) with a positive SARS-CoV-2 test. Their close contacts had mild to severe symptoms and three of them died. In the SARS-CoV-2 infection different inflammatory pathways are altered where colchicine reduces cytokine levels as well as the activation of macrophages, neutrophils, and the inflammasome. The possible mechanisms that colchicine may use to prevent acute respiratory distress syndrome (ARDS) in patients with COVID-19 infection are also reviewed in this article.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Respiratory Distress Syndrome
/
Colchicine
/
Tubulin Modulators
/
COVID-19 Drug Treatment
/
Anti-Inflammatory Agents
Type of study:
Case report
/
Diagnostic study
/
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Adult
/
Female
/
Humans
/
Middle aged
Language:
English
Journal:
Reumatol Clin (Engl Ed)
Year:
2021
Document Type:
Article
Affiliation country:
J.reumae.2020.05.008
Similar
MEDLINE
...
LILACS
LIS